U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Guideline for the pharmacological treatment of hypertension in adults [Internet]. Geneva: World Health Organization; 2021.

Cover of Guideline for the pharmacological treatment of hypertension in adults

Guideline for the pharmacological treatment of hypertension in adults [Internet].

Show details

References

(1)
Cardiovascular diseases (CVDs). Key facts. 17May2017 [website] (https://www​.who.int/news-room​/fact-sheets​/detail/cardiovascular-diseases-(cvds), accessed 31 March 2021).
(2)
Hypertension. Key facts. 13September2019 [website] (https://www​.who.int/news-room​/fact-sheets​/detail/hypertension, accessed 31 March 2021).
(3)
Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. Geneva: World Health Organization; 2007.
(4)
HultcrantzM, RindD, AklEA, TreweekS, MustafaRA, IorioA, et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4–13. doi: 10.1016/j.jclinepi.2017.05.006. [PMC free article: PMC6542664] [PubMed: 28529184] [CrossRef]
(5)
BalshemH, HelfandM, SchünemannHJ, OxmanAD, KunzR, BrozekJ. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406. doi: 10.1016/j.jclinepi.2010.07.015. [PubMed: 21208779] [CrossRef]
(6)
ShahajO, DennenyD, SchwappachA, PearceG, EpiphaniouE, ParkeH, et al. Supporting self-management for people with hypertension: a meta-review of quantitative and qualitative systematic reviews. J Hypertens. 2019;37(2):264–279. doi: 10.1097/HJH.0000000000001867. [PubMed: 30020240] [CrossRef]
(7)
MeiqariL, NguyenT-P-L, EssinkD, ZweekhorstM, WrightP, ScheeleF. Access to hypertension care and services in primary health-care settings in Vietnam: a systematic narrative review of existing literature. Glob Health Action. 2019;12(1):1–11. doi: 10.1080/16549716.2019.1610253. [PMC free article: PMC6534204] [PubMed: 31120345] [CrossRef]
(8)
KostovaD, SpencerG, MoraAE, CobbLAK, HusainMJ, DattaBK, et al. The cost effectiveness of hypertension management in low-income and middle-income countries: a review. BMJ Public Global Health. 2020;e002213. doi: 10.1136/bmjgh-2019-002213. [PMC free article: PMC7484861] [PubMed: 32912853] [CrossRef]
(9)
MurrayCJ, LauerJA, HutubessyRC, NiessenL, TomijimaN, RodgersA, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003Mar1;361(9359):717–25. doi: 10.1016/S0140-6736(03)12655-4. Erratum in: Lancet. 2005 Jul 16-22;366(9481):204. PMID: 12620735. [PubMed: 12620735] [CrossRef]
(10)
ConstantiM, FloydCN, GloverM, BoffaR. WierzbickiAS, McManusRJ. Cost-effectiveness of initiating pharmacological treatment in stage one hypertension based on 10-year cardiovascular disease risk. Hypertension. 2021;77:682–691. doi: 10.1161/HYPERTENSIONAHA.120.14913. [PMC free article: PMC7803450] [PubMed: 33342242] [CrossRef]
(11)
MoranAE, OddenMC, ThanataveeratA, TzongKY, RasmussenPW, GuzmanD. Cost-effectiveness of hypertension therapy according to 2014 guidelines. NEJM. 2015;372(5):447–55. doi: 10.1056/NEJMsa1406751. [PMC free article: PMC4403858] [PubMed: 25629742] [CrossRef]
(12)
RosendaalTA, HendriksME, VerhagenMD, BolarinwaOA, SanyaEO, KoloPM, et al. Correction: costs and cost-effectiveness of hypertension screening and treatment in adults with hypertension in rural Nigeria in the context of a health insurance program. PLoS ONE. 2016Jun27;11(9):e0162421. doi: 10.1371/journal.pone.0162421. [PMC free article: PMC5019417] [PubMed: 27617836] [CrossRef]
(13)
RubinsteinA, ColantonioL, BardachA, CaporaleJ, MartíSG, KopitowskiK, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;10:627. doi: 10.1186/1471-2458-10-627. [PMC free article: PMC2970607] [PubMed: 20961456] [CrossRef]
(14)
RichmanIB, FairleyM, JørgensenME, SchulerA, OwensDK, Goldhaber-FiebertJD. Cost-effectiveness of intensive blood pressure management. JAMA Cardiol. 2016;1(8):872–879. doi: 10.1001/jamacardio.2016.3517. [PMC free article: PMC5892423] [PubMed: 27627731] [CrossRef]
(15)
BressAP, BellowsBK, KingJB, HessR, BeddhuS, ZhangZ. Cost-effectiveness of intensive versus standard blood-pressure control. NEJM. 2017;377(8):745–755. doi: 10.1056/NEJMsa1616035. [PMC free article: PMC5708850] [PubMed: 28834469] [CrossRef]
(16)
OddenMC, MoranAE, CoxsonPG, PeraltaCA, GoldmanL, Bibbins-DomingoK. Gait speed as a guide for BP targets in older adults: a modeling study. J Am Geriatr Soc. 2016;64(5):1015–23. [PMC free article: PMC5030071] [PubMed: 27225357]
(17)
Federal Reserve Bank economic data [online database] (https://fred​.stlouisfed​.org/series/NYGDPPCAPCDLMC). Cited in Kostova et al., 2020.
(18)
PedrosaRP, DragerLF, GonzagaCC, SousaMG, de PaulaLK, AmaroACS, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811–7. doi: 10.1161/hypertensionaha.111.179788. [PubMed: 21968750] [CrossRef]
(19)
RimoldiSF, ScherrerU, MesserliFH. Secondary arterial hypertension: when, who, and how to screen?Eur Heart J. 2013;35(19):1245–54. doi: 10.1093/eurheartj/eht534. [PubMed: 24366917] [CrossRef]
(20)
ViraniSS, AlonsoA, BenjaminEJ, BittencourtMS, CallawayCW, CarsonAP, et al. Heart disease and stroke statistics – 2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. doi: 10.1161/CIR.0000000000000757. [PubMed: 31992061] [CrossRef]
(21)
ParkC, FangJ, HawkinsNA, WangG. Comorbidity status and annual total medical expenditures in US hypertensive adults. Am J Prev Med. 2017;53(6s2):S172–s81. doi: 10.1016/j.amepre.2017.07.014. [PMC free article: PMC5836318] [PubMed: 29153118] [CrossRef]
(22)
KirklandEB, HeincelmanM, BishuKG, SchumannSO, SchreinerA, AxonRN, et al. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003-2014. J Am Heart Assoc. 2018;7(11):e008731. doi: 10.1161/JAHA.118.008731. [PMC free article: PMC6015342] [PubMed: 29848493] [CrossRef]
(23)
MoserM. The cost of treating hypertension can we keep it under control without compromising the level of care?Am J Hypertens. 1998;11:120S–127S. doi: 10.1016/s0895-7061(98)00106-x. [PubMed: 9717853] [CrossRef]
(24)
KarmaliKN, Lloyd-JonesDM, van der LeeuwJ, GoffJrDC, YusufS, ZanchettiA, et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus BP: a meta-analysis of individual participant data. PLoS Med. 2018;15(3)e1002538. doi: 10.1371/journal.pmed.1002538. [PMC free article: PMC5860698] [PubMed: 29558462] [CrossRef]
(25)
OdutayoA, GillP, ShepherdS, AkingbadeA, HopewellS, TennankoreK, et al. Income disparities in absolute cardiovascular risk and cardiovascular risk factors in the United States, 1999-2014. JAMA Cardiol. 2017;2(7):782–790. doi:10.1001/jamacardio.2017.1658. [PMC free article: PMC5710615] [PubMed: 28593301] [CrossRef]
(26)
GazianoTA, SteynK, CohenDJ, WeinsteinMC, OpieLH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112(23):3569–76). doi: 10.1161/CIRCULATIONAHA.105.535922. [PubMed: 16330698] [CrossRef]
(27)
EttehadD, EmdinCA, KiranA, AndersonSG, CallenderT, EmbersonJ, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. doi: 10.1016/S0140-6736(15)01225-8. [PubMed: 26724178] [CrossRef]
(28)
SeeleyA, PrynnJ, PereraR, StreetR, DavisD, EtyangAO. Pharmacotherapy for hypertension in sub-Saharan Africa: a systematic review and network meta-analysis. BMC Med. 2020;18(1):75. doi: 10.1186/s12916-020-01530-z. [PMC free article: PMC7099775] [PubMed: 32216794] [CrossRef]
(29)
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy. Hypertension. 2003;42:239–246. doi: 10.1161/01.HYP.0000086521.95630.5A. [PubMed: 12925554] [CrossRef]
(30)
JuliusS, KjeldsenSE, BrunnerH, HanssonL, PlattF, EkmanS, et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16(7):544–8. doi: 10.1016/s0895-7061(03)00904-x. [PubMed: 12850387] [CrossRef]
(31)
NissenSE, TuzcuEM, LibbyP, ThompsonPD, GhaliM, GarzaD, et al.; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–25. doi: 10.1001/jama.292.18.2217. [PubMed: 15536108] [CrossRef]
(32)
WrightJT, DunnJK, CutlerJA, DavisBR, CushmanWC, FordCEet al; for the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293(13):1595–1608. doi:10.1001/jama.293.13.1595. [PubMed: 15811979] [CrossRef]
(33)
MorganTO, AndersonAI, MacInnisRJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens, 2001;14(3): 241–247. doi: 10.1016/S0895-7061(00)01266-8. [PubMed: 11281235] [CrossRef]
(34)
SareliP, RadevskiIV, ValtchanovaZP, LibhaberE, CandyGP, Den HondE, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med. 2001;161(7):965. doi: 10.1001/archinte.161.7.965. [PubMed: 11295959] [CrossRef]
(35)
AarabiM. SkinnerJ, PriceCE, Jackson, PR. Patients’ acceptance of antihypertensive therapy to prevent cardiovascular disease: a comparison between South Asians and Caucasians in the United Kingdom. Eur J Cardiovasc Prev Rehabil. 2008Feb;15(1):59–66. doi: 10.1097/HJR.0b013e3282f07973. [PubMed: 18277187] [CrossRef]
(36)
FragassoG, MarantaF, MontanaroC, SalernoA, TorlascoC, MargonatoA. Pathophysiologic therapeutic targets in hypertension: a cardiological point of view. Expert Opin Ther Targets. 2012;16(2):179–193. doi: 10.1517/14728222.2012.655724. [PubMed: 22280298] [CrossRef]
(37)
NugentR, BrowerE, CraviotoA, KoehlmoosT. A cost-benefit analysis of a National Hypertension Treatment Program in Bangladesh. Prev Med. 2017Dec;105S:S56–S61. doi: 10.1016/j.ypmed.2017.08.014. [PubMed: 28827074] [CrossRef]
(38)
GadM, LordJ, ChalkidouK, AsareB, LutterodtMG, RuizF. Supporting the development of evidence-informed policy options: an economic evaluation of hypertension management in Ghana. Value Health. 2020;23(2):171–179. doi: 10.1016/j.jval.2019.09.2749. [PMC free article: PMC7065042] [PubMed: 32113622] [CrossRef]
(39)
EkwunifeOI, OkaforCE, EzendukaCC, UdeogaranyaPO. Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis. Cost Eff Resour Alloc. 2013;11(1):2. doi: 10.1186/1478-7547-11-2. [PMC free article: PMC3567962] [PubMed: 23343250] [CrossRef]
(40)
ParkC, WangG, DurthalerJM, FangJ. Cost-effectiveness analyses of antihypertensive medicines: a systematic review. Am J Prev Med. 2017;53(6S2):S131–S142. doi: 10.1016/j.amepre.2017.06.020. [PMC free article: PMC5836308] [PubMed: 29153114] [CrossRef]
(41)
ReaF, CorraoG, MerlinoL, ManciaG. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;72:846–853. doi: 10.1161/HYPERTENSIONAHA.118.11308. [PubMed: 30354712] [CrossRef]
(42)
SherrillB, HalpernM, KhanS, ZhangJ, PanjabiS. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens. 2011;13(12):898–909. doi: 10.1111/j.1751-7176.2011.00550.x. [PMC free article: PMC8108883] [PubMed: 22142349] [CrossRef]
(43)
Krousel-WoodM, ThomasS, MuntnerP, MoriskyD. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19(4):357–362. doi: 10.1097/01.hco.0000126978.03828.9e. [PubMed: 15218396] [CrossRef]
(44)
FujikawaK, HasebeN, KikuchiK; NICE-Combi Study Group. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension – the Nifedipine and Candesartan Combination (NICE-Combi) Study. Hypertens Res. 2005;28(7):585–91. doi: 10.1291/hypres.28.585. [PubMed: 16335887] [CrossRef]
(45)
DeshmukhKBS, QianJ, GarzaK, WrightBM, ZengP, Ganduglia CazabanCM, et al. Health care costs associated with addition, titration, and switching antihypertensive medications after first-line treatment: results from a commercially insured sample. J Manag Care Spec Pharm. 2017;23(6):691–699. doi: 10.18553/jmcp.2017.23.6.691. [PMC free article: PMC10398079] [PubMed: 28530527] [CrossRef]
(46)
RenM, XuanD, LuY, FuY, XuanJ. Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China. J Med Econ. 2020;23(4):394–400. doi: 10.1080/13696998.2019.1699799. [PubMed: 31782677] [CrossRef]
(47)
ChrysantSG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Invest. 2008;28(11):713–734. doi: 10.2165/00044011-200828110-00005. [PubMed: 18840014] [CrossRef]
(48)
MillsKT, BundyJD, KellyTN, ReedJE, KearneyPM, ReynoldsK, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441–450. doi: 10.1161/CIRCULATIONAHA.115.018912. [PMC free article: PMC4979614] [PubMed: 27502908] [CrossRef]
(49)
SalamA, HuffmanM, KanukulaR, PrasadEH, SharmaA, HellerD, et al. Two-drug fixed-dose combinations of blood-pressure lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. J Clin Hypertens. 2020;22:1769–1779. doi: 10.1111/jch.14009. [PMC free article: PMC8030031] [PubMed: 32815663] [CrossRef]
(50)
ChowCK, TeoKK, RangarajanS, IslamS, GuptaR, AvezumA, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310: 959–968. doi: 10.1001/jama.2013.184182. [PubMed: 24002282] [CrossRef]
(51)
ChobanianAV, BakrisGL, BlackHR, CushmanWC, GreenLA, IzzoJrJL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2. [PubMed: 14656957] [CrossRef]
(52)
KishoreSP, SalamA, RodgersA, JaffeMG, FriedenT. Fixed-dose combinations for hypertension. Lancet. 2019;392(10150):819–820. doi: 10.1016/S0140-6736(18)31814-2. [PubMed: 30215377] [CrossRef]
(53)
DiPetteDJ, SkeeteJ, Ridley, E, Campbell, NRC, Lopez-JaramilloP, KishoreSP, et al. Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. J Clin Hypertens. 2019;21(1):4–15. doi: 10.1111/jch.13426. [PMC free article: PMC8030442] [PubMed: 30480368] [CrossRef]
(54)
MarinierK, MacouillardP, de ChampvalinsM, DeltourN, PoulterN, ManciaG, et al. Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: a propensity score-matched cohort study in the UK Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2019;28(12): 1572–1582. doi: 10.1002/pds.4884. [PMC free article: PMC6916605] [PubMed: 31482621] [CrossRef]
(55)
NegiS, NeupaneD, SahooSW, MahajanT, SwaroopK, MoranAE, et al. Prices of combination medicines and single-molecule anti-hypertensive medicines in India’s private health care sector. J Clin Hypertens. 2021;23(4):738–743. doi: 10.1111/jch.14143. [PMC free article: PMC8678655] [PubMed: 33369089] [CrossRef]
(56)
AngeliF, ReboldiG, MazzottaG, GarofoliM, RamundoE, PoltonieriC, et al. Fixed-dose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev. 2012;19(2):51–54. doi: 10.1007/BF03262453. [PubMed: 22867089] [CrossRef]
(57)
Jaffe MG LeeGA, YoungJD, SidneyS, GoAS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699–705. doi: 10.1002/pds.4884. [PMC free article: PMC4270203] [PubMed: 23989679] [CrossRef]
(58)
Sprint Research Group. Randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116. doi: 10.1056/NEJMoa1511939. [PMC free article: PMC4689591] [PubMed: 26551272] [CrossRef]
(59)
MuradMH, Larrea-MantillaL, HaddadA, Spencer-BonillaG, SerranoV, Rodriguez-GutierrezR, et al. Antihypertensive agents in older adults: a systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. 2019;104(5):1575–1584. doi: 10.1210/jc.2019-00197. [PubMed: 30903690] [CrossRef]
(60)
ReboussinDM, AllenNB, GriswoldME, GuallarE, HongY, LacklandDT, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e595–e616. doi: 10.1161/CIR.0000000000000601. [PubMed: 30354656] [CrossRef]
(61)
ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med2010;362:1575–1585. doi: 10.1056/NEJMoa1001286. [PMC free article: PMC4123215] [PubMed: 20228401] [CrossRef]
(62)
SPS3 Study Group, BenaventeOR, CoffeyCS, ConwitR, HartRG, McClureLA, PearceLA. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382(9891):507–15. doi: 10.1016/S0140-6736(13)60852-1. [PMC free article: PMC3979302] [PubMed: 23726159] [CrossRef]
(63)
BangaloreS, TokluB, GianosE, SchwartzbardA, WeintraubH, OgedegbeG, et al. Optimal systolic BP target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;130(6):707–719.e708. doi: 10.1016/j.amjmed.2017.01.004. [PubMed: 28109971] [CrossRef]
(64)
BundyJD, LiC, StuchlikP, BuX, KellyTN, MillsKT, et al. Systolic BP reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiology. 2017;2(7):775–781. doi: 10.1001/jamacardio.2017.1421. [PMC free article: PMC5710614] [PubMed: 28564682] [CrossRef]
(65)
HowardK, WhiteS, SalkeldG, McDonaldS, CraigJ, ChadbanS, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health. 2010;13(2):196–208. doi: 10.1111/j.1524-4733.2009.00668.x. [PubMed: 19878493] [CrossRef]
(66)
BirtwhistleRV, GodwinMS, DelvaMD, CassonRI, LamM, MacDonaldSE, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ. 2004;328(7433):204. doi: 10.1136/bmj.37967.374063.EE. [PMC free article: PMC318487] [PubMed: 14726370] [CrossRef]
(67)
XuW, GoldbergSI, ShubinaM, TurchinA. Optimal systolic BP target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ. 2015;350:h158. doi: 10.1136/bmj.h158. [PMC free article: PMC4353282] [PubMed: 25655523] [CrossRef]
(68)
AmbrosiusWT, SinkKM, FoyCG, BerlowitzDR, CheungAK, CushmanWC, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Trials. 2014;11(5):532–546. doi: 10.1177/1740774514537404. [PMC free article: PMC4156910] [PubMed: 24902920] [CrossRef]
(69)
CushmanWC, GrimmJrRH, CutlerJA, GregoryWE, CapesS, CorsonMA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):44i–55i. doi: 10.1016/j.amjcard.2007.03.005. [PubMed: 17599425] [CrossRef]
(70)
Gwadry-SridharFH, ManiasE, LalL, SalasM, HughesDA, Ratzki-LeewingA, et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health. 2013;16(5):863–871. doi: 10.1016/j.jval.2013.03.1631. [PubMed: 23947982] [CrossRef]
(71)
WalkerRC, TongA, HowardK, PalmerSC. Patient expectations and experiences of remote monitoring for chronic diseases: Systematic review and thematic synthesis of qualitative studies. Int J Med Inform. 2019;124:78–85. doi: 10.1016/j.ijmedinf.2019.01.013. [PubMed: 30784430] [CrossRef]
(72)
JaanaM, PareG, SicotteC. Hypertension home telemonitoring: current evidence and recommendations for future studies. Dis Manage Health Outcomes. 2007;15(1):19–31. doi: 10.2165/00115677-200715010-00004. [CrossRef]
(73)
GreerN, BolducJ, GeurkinkE, KoellerE, RectorT, OlsonK, et al. Pharmacist-led chronic disease management: a systematic review of effectiveness and harms compared with usual care. Ann Intern Med. 2016;165(1):30–40. doi: 10.7326/M15-3058. [PubMed: 27111098] [CrossRef]
(74)
AnandTN, JosephLM, GeethaAV, PrabhakaranD, JeemonP. Task sharing with non-physician health-care workers for management of blood pressure in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Glob Health. 2019;7(6):e761–e771. doi: 10.1016/S2214-109X(19)30077-4. [PMC free article: PMC6527522] [PubMed: 31097278] [CrossRef]
(75)
TuckerP, SheppardJP, StevensR, BosworthHB, BoveA, BrayEP, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLOS Med. 2017;14(9):e1002389. doi: 10.1371/journal.pmed.1002389. [PMC free article: PMC5604965] [PubMed: 28926573] [CrossRef]
(76)
FisherNDL, FeraLE, DunningJR, DesaiS, MattaL, LiquoriV, et al. Development of an entirely remote, non-physician led hypertension management program. Clin Cardiol. 2019;42(2):285–291. doi: 10.1002/clc.23141. [PMC free article: PMC6712321] [PubMed: 30582181] [CrossRef]
(77)
BhanbhroS, DrennanVM, GrantR, HarrisR. Assessing the contribution of prescribing in primary care by nurses and professionals allied to medicine: a systematic review of literature. BMC Health Serv Res. 2011;11:330. doi: 10.1186/1472-6963-11-330. [PMC free article: PMC3248914] [PubMed: 22136294] [CrossRef]
(78)
HobsonRJ, ScottJ, SuttonJ. Pharmacists and nurses as independent prescribers: exploring the patient’s perspective. Fam Pract. 2010;27(1):110–120. doi: 10.1093/fampra/cmp070. [PubMed: 19858124] [CrossRef]
(79)
StewartDC, GeorgeJ, BondCM, CunninghamITS, DiackHL, McCaigDJ. Exploring patients’ perspectives of pharmacist supplementary prescribing in Scotland. Pharm World Sci. 2008;30(6):892–897. doi: 10.1007/s11096-008-9248-x. [PubMed: 18787976] [CrossRef]
(80)
JacobV, ChattopadhyaySK, ThotaAB, ProiaKK, NjieG, HopkinsDP, et al. Economics of team-based care in controlling BP: a community guide systematic review. Am J Prev Med. 2015;49(5):772–783. doi: 10.1016/j.amepre.2015.04.003. [PMC free article: PMC4685935] [PubMed: 26477804] [CrossRef]
(81)
KulchaitanaroajP, BrooksJM, ChaiyakunaprukN, GoedkenAM, ChrischillesEA, CarterBL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. J Hypertens. 2017;35(1):178–187. doi: 10.1097/HJH.0000000000001126. [PubMed: 27684354] [CrossRef]
(82)
KeasleyJ, OyebodeO, ShantikumarS, ProtoW, McGranahanM, SabouniA, KidyF. A systematic review of the burden of hypertension, access to services and patient views of hypertension in humanitarian crisis settings. BMJ Glob Health. 2020;5(11): e002440. doi: 10.1136/bmjgh-2020-002440. [PMC free article: PMC7654140] [PubMed: 33168520] [CrossRef]
(83)
SekkarieM, MuradL, Al-MakkiA, Al-SaghirF, RifaiO, IsrebM. End-stage kidney disease in areas of armed conflicts: challenges and solutions. Semin Nephrol. 2020;40(4):354–362. doi: 10.1016/j.semnephrol.2020.06.003. [PubMed: 32800286] [CrossRef]
(84)
Al-MakkiA, RifaiAO, MuradL, ZanabliAR, KayalA, SoudanK, et al. The Syrian National Kidney Foundation: response for the need of kidney patients during the crisis. Avicenna J Med. 2014Jul;4(3):54–7. doi: 10.4103/2231-0770.133331. [PMC free article: PMC4065460] [PubMed: 24982825] [CrossRef]
(85)
JawadM, VamosEP, NajimM, RobertsB, MillettC. Impact of armed conflict on cardiovascular disease risk: a systematic review. Heart. 2019;105:1388–94. doi: 10.1136/heartjnl-2018-314459. [PubMed: 31138670] [CrossRef]
(86)
HowardJT, SosnovJA, JanakJC, GunlapalliAV, PetteyWB, WalkerLE, et al. Associations of initial injury severity and posttraumatic stress disorder diagnoses with long-term hypertension risk after combat injury. Hypertension. 2018;71:824–32. doi: 10.1161/HYPERTENSIONAHA.117.10496. [PubMed: 29555664] [CrossRef]
(87)
DoocyS, LylesE, FahedZ, MikannaA, KontunenK, BurnhamG. Characteristics of Syrian and Lebanese diabetes and hypertension patients in Lebanon. Open Hypertens J. 2018;10:60–75. doi: 10.2174/1876526201810010060. [CrossRef]
(88)
SunX-C, ZhouX-F, ChenS, LiuY-X, WangY-J, ZhangW, et al. Clinical characteristics of hypertension among victims in temporary shield district after Wenchuan earthquake in China. Eur Rev Med Pharmacol Sci. 2013;17:912–6. PMID: 23640437. [PubMed: 23640437]
(89)
KarioK. Disaster hypertension - its characteristics, mechanism, and management. Circ J. 2012;76(3):553–62. doi: 10.1253/circj.cj-11-1510. [PubMed: 22327030] [CrossRef]
(90)
Médecins Sans Frontières. Clinical guidelines: diagnostic and treatment manual. Author; 2013.
(91)
WHO. Interagency emergency health kit2017 [website] (https://www​.who.int/emergencies​/kits/iehk/en/, accessed March 2021).
(92)
COVID-19 and hypertension. Scientific Brief. Geneva: World Health Organization; June2021 (WHO​/2019-nCoV/Sci_Brief​/Hypertension/2021.1, accessed July 2021).
(93)
RichardsonS, HirschJS, NarasimhanM, CrawfordJM, McGinnT, the Northwell COVID-19 Research Consortium, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775. Erratum in: JAMA. 2020 May 26;323(20):2098. [PMC free article: PMC7177629] [PubMed: 32320003] [CrossRef]
(94)
XieJ, TongZ, GuanX, DuB, QiuH. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020;3(4):e205619. doi: 10.1001/jamanetworkopen.2020.5619. Erratum in: JAMA Netw Open. 2020 May 1;3(5):e208147. [PMC free article: PMC7148440] [PubMed: 32275319] [CrossRef]
(95)
HoffmannM, Kleine-WeberH, SchroederS, KrügerN, HerrlerT, ErichsenS, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052. [PMC free article: PMC7102627] [PubMed: 32142651] [CrossRef]
(96)
VaduganathanM, VardenyO, MichelT, McMurrayJJV, PfefferMA, SolomonSD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–1659. doi: 10.1056/NEJMsr2005760. [PMC free article: PMC7121452] [PubMed: 32227760] [CrossRef]
(97)
COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. Scientific Brief. Geneva: World Health Organization; May2020 (WHO​/2019-nCoV/Sci_Brief/ACE-I/2020.1, accessed July 2021).
(98)
SparksMA, HiremathS, et al. ACE2 and hypertension [website]. (http://www​.nephjc.com/news/covidace2, accessed 19 February 2021).
(99)
KompotiatisP, GarovicVD. Diagnosis, treatment, and outcomes of hypertensive pregnancy disorders. In: EdwardsEW, DiPetteDJ, editors. Hypertension: a case-based approach. New Delhi: Jaypee Brothers Medical Publishers Ltd; 2020.
(100)
KuklinaEV, AyalaC, CallaghanWM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol. 2009;113(6):1299–306. doi: 10.1097/AOG.0b013e3181a45b25. [PubMed: 19461426] [CrossRef]
(101)
CreangaAA, BergCJ, SyversonC, SeedK, BruceFC, CallaghanWM. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol. 2015;125(1):5–12. doi: 10.1097/AOG.0000000000000564. [PubMed: 25560097] [CrossRef]
(102)
AbalosE, DuleyL, SteynDW, GialdiniC. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Syst Rev. 2018;10(10):CD002252. doi: 10.1002/14651858.CD002252.pub4. [PMC free article: PMC6517078] [PubMed: 30277556] [CrossRef]
© World Health Organization 2021.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Bookshelf ID: NBK573620

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...